key: cord-0829085-t6pe4uzn
authors: Qin, Wei; Dong, Fen; Zhang, Zhu; Hu, Bingzhu; Chen, Shi; Zhu, Ziyang; Li, Fajiu; Wang, Xiaojiang; Zhang, Yunxia; Wang, Yimin; Zhen, Kaiyuan; Wang, Jing; Elalamy, Ismaïl; Li, Chenghong; Zhai, Zhenguo; Davidson, Bruce L.; Wang, Chen
title: Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era
date: 2020-11-23
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.11.020
sha: 34ead6d7b8239b7eaced3c31a2ea7cc8fc3307c0
doc_id: 829085
cord_uid: t6pe4uzn

nan

Co. LTD, China) use was recorded, administered as prophylactic dosage 3000-5000 U/day or the therapeutic dose was based on actual body weight (100U/kg, q12h). All patients were given intravenous methylprednisolone according to our guideline, 40 or 80 mg/day. The primary outcome was mortality within 28 days after hospital admission. Patients discharged earlier were followed to day 28 to ascertain survival.

Data were summarized as number (percentage) for categorical variables and mean (SD) or median (interquartile ranges [IQR] ) for continuous variables as appropriate.

T-test, Mann Whitney U test, Chi-square test or Fisher exact test were used to compare differences in baseline characteristics, treatment and complications. To explore an association of LMWH treatment with 28-day mortality, we fitted multivariable Cox regression model with covariates adjusted. The proportional hazard assumption was tested and if the assumption was violated, an extended Cox analysis with time-varying covariates was performed. The violating covariates were handled by their interactions with followed-up time. Patients alive at day 28 were regarded as right-censored. Based on the up-to-date knowledge on COVID-19 and prior research, we constructed a causal diagram to visually illustrate the potential effect of exposures on fatal outcomes (Fig.A.1 ). Five blocks of factors were analyzed: typical demographic information, comorbidities, COVID-19 severity, coagulopathy on admission, and treatments provided in hospital. In our prior research, normal D-dimer on admission and day 3 were highly predictive of 28-day survival [2] . In this study, J o u r n a l P r e -p r o o f Journal Pre-proof LMWH treatment was the major focus and D-dimer elevation was an important confounder requiring adjustment. Likewise, other factors potentially associated with mortality were adjusted in the multivariable Cox model. The hypothetical links from demographical characteristics, clinical features, and treatments to mortality at 28 day were included in a directed acyclic graph. Variables were evaluated for multicollinearity and independence. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, North Carolina, USA) with two-tailed p<0.05 considered significant.

Altogether, 761 adult patients with confirmed COVID-19 were consecutively admitted to hospital during the study period. We excluded 2 patients who died on admission and another 10 patients whose D-dimer data were unavailable, leaving 749 patients. The mean (SD) age was 60 (15) years and 48% were men. The admitted patients had an overall SOFA score of 1 (0-2) on admission. Fever and cough were (Table A. 2).

Analyzing the relationship between disease severity and anticoagulation on mortality, LMWH use was associated with decreased mortality in the subgroup of patients with SOFA score ≥3 [0.17 (0.06-0.43)] (Table A. 3). The interaction was statistically significant (p<0.01), suggesting SOFA might play a role in the influence of LMWH treatment on mortality.

Individuals with elevated D-dimer at admission had a poorer prognosis [2] and anticoagulant therapy may improve their survival. In this pragmatic study, LMWH treatment was administered at the discretion of physicians and disproportionately delivered to elderly male patients with higher SOFA score and elevated D-dimer.

Given the potential bias due to non-randomized nature of observational study, we J o u r n a l P r e -p r o o f Journal Pre-proof constructed a diagram (Fig. A.1) with unidirectional arrows to present causal effects on COVID-19 and performed a hypothesis-driven analysis according to the guideline on casual inference in observational studies [4] . The protective association between LMWH and mortality suggested survival benefit of anticoagulation. The decrease in death risk might be attributable to LMWH's anticoagulant and other pleiotropic effects [5] . Other treatments like corticosteroids were mainly delivered to older male patients. Patients receiving corticosteroid treatment had increased death risk, consistent with a prior report of a nearly three-fold increase in death compared to patients not receiving steroid [6] . In our study, corticosteroid recipients were at a significant 2.59-fold increased death risk. While some researchers advocate against corticosteroid use for COVID-19 [7] , whereas other experts recommended it [8] . In a randomized clinical trial, dexamethasone use resulted in lower 28-day mortality among patients receiving either invasive mechanical ventilation or oxygen alone [9] .

For immunoglobulin therapy, also routinely administered in our study, there was an insignificant trend toward decreased death. Elsewhere, a case series demonstrated recovery of debilitated COVID-19 patients after early high-dose immunoglobulin [10] .

In our observational cohort study conducted early in the epidemic era, LMWH, given at prophylactic dosage, was the predominant anticoagulant for COVID-19 patients and associated with survival. Whether early routine LMWH use, perhaps at higher 

COVID-19 and its implications for thrombosis and anticoagulation

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad

Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19

The association between treatment with heparin and survival in patients with Covid-19

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

On the use of corticosteroids for 2019-nCoV pneumonia

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open forum infectious diseases